Luteinizing hormone-releasing hormone antagonist cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord

Authors: Gonzalez-Barcena D.; Vadillo-Buenfil M.; Cortez-Morales A.; Fuentes-Garcia M.; Cardenas-Cornejo I.; Comaru-Schally A.M.; Schally A.V.

Source: Urology, Volume 45, Number 2, February 1995 , pp. 275-281(7)

Publisher: Elsevier

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Language: English

Document Type: Research article

DOI: 10.1016/0090-4295(95)80018-2

This article is hosted on another website.

You may be required to register, activate a subscription or purchase the article before you can obtain the full text.

Proceed

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A